Corbus Pharmaceuticals Files 8-K

Ticker: CRBP · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1595097

Sentiment: neutral

Topics: 8-K, corporate-filing, pharmaceuticals

TL;DR

Corbus Pharma dropped an 8-K on 10/20 covering 10/18 events - check it for Reg FD, other news, and financials.

AI Summary

Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on October 20, 2025, reporting events as of October 18, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, incorporated in Delaware, is in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing provides updates on Corbus Pharmaceuticals' corporate activities and financial reporting, which are crucial for investors to understand the company's current status and future outlook.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting standard corporate events and financial information, not indicating immediate significant risks.

Key Numbers

Key Players & Entities

FAQ

What specific events are being disclosed under 'Other Events'?

The provided text does not detail the specific 'Other Events' disclosed in the filing.

Are there any material updates in the 'Financial Statements and Exhibits' section?

The filing indicates the inclusion of 'Financial Statements and Exhibits' but does not specify their content or any material updates within the provided text.

What is the significance of the 'Regulation FD Disclosure' item?

Regulation FD Disclosure indicates that the company is making public disclosures to prevent selective disclosure of material non-public information.

When was Corbus Pharmaceuticals Holdings, Inc. incorporated?

Corbus Pharmaceuticals Holdings, Inc. was incorporated in Delaware.

What is the company's primary business sector?

The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,184 words · 5 min read · ~4 pages · Grade level 8.9 · Accepted 2025-10-20 07:53:43

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 18, 2025, Corbus Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing data from its Phase 1/2 clinical study of CRB-701 (SYS6002) that was presented at the 2025 European Society for Medical Oncology Congress ("ESMO25") on October 19, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission (the "SEC"), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On October 18, 2025, the Company announced data from its Phase 1/2 clinical study of CRB-701 that was presented at ESMO25 on October 19, 2025. Data as of September 1, 2025 was presented from 167 patients, of whom 122 1 were evaluable for efficacy. The tumor types being investigated were head and neck squamous cell carcinoma (HNSCC, n=41), cervical cancer (n=37) and locally advanced/metastatic urothelial (mUC, n=23) tumors. In addition, 21 patients who had other solid-tumor types were enrolled during dose escalation. The multi-center Phase 1/2 study is being conducted in the U.S and Europe. The study was designed as an "all comers" trial with no enrollment restrictions for biomarkers (Nectin-4, PDL-1 or HPV status) or the number of prior lines of therapy. Patients were heavily pretreated with a median of 3 prior lines of therapy (range: 1–9), and the mean age was 60 years (range: 30–90). Baseline performance status, as assessed by the Eastern Cooperative Oncology Group (ECOG), was 2 for all patients, with 43.1% classified as ECOG 0, 55.1% as ECOG 1, and 1.8% as ECOG 2. --------------------------- 1 122 evaluable patients includes 84 patients with either HNSCC, cervical or mUC tumors dosed at 2.7 mg/kg (n=38) or 3.6 mg/kg (n=46), 7 patients with either HNSCC, cervical or mUC tumors dosed during dose escalation at 1.8 mg/kg, 21 patients who had other solid-tumor types that were enrolled during dose escalation, 8 non-evaluable patients, 1 patient with a -60.7% reduction in the size of mUC tumor not included in ORR and DCR calculations due to missing data and 1 patient with a HNSCC tumor dosed with the combination of CRB-701 (at 2.7 mg/kg) and pembrolizumab. Efficacy in Response Evaluable Patients (n=84) dosed either at 2.7 mg/kg or 3.6 mg/kg HNSCC (n=33) Dose 2.7 mg/kg 3.6 mg/kg ORR* 33.3% (4/12) 47.6% (10/21) DCR** 75.0% 61.9% Response confirmation*** All confirmed 7 confirmed 3 unconfirmed: 1 discontinued

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated October 18, 2025 99.2 Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: October 20, 2025 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing